5-Amino-1MQ Dosage: A Preclinical Compound
Last updated September 26, 2026 · Reviewed by Grey Peptides Editorial Board · ✓ Primary-sourced
← 5-Amino-1MQ encyclopedia entry · See also: NAD+ dosage · Regulatory tracker
5-Amino-1MQ is a small-molecule NNMT inhibitor — not a peptide — with no published human trials, included here because it is grouped with peptides in fat-loss protocols. It is not approved. The figure below reflects community practice, documented for education — not instructions for use.
Educational information, not medical advice. The doses on this page come from approved labels, published studies and, where no study exists, amounts reported by users. None is a recommendation for you. An unapproved compound has no established safe or effective human dose, and products sold for “research use only” are not made or tested for people. Talk to a doctor before acting on anything on this site, including before you start, stop or change any medicine or dose. Full medical disclaimer.
The short version
5-Amino-1MQ inhibits NNMT (nicotinamide-N-methyltransferase), an enzyme involved in nicotinamide metabolism. In animal and cell studies, blocking NNMT is linked to higher intracellular NAD+ and reduced fat storage, which is why it is marketed for fat loss and metabolic health. The decisive context for any dose is that this evidence is entirely preclinical — there are no published human trials to anchor a dose, a safety profile, or an efficacy claim.
What community protocols report
Community-reported. Amounts users report, recorded for education. Not a recommendation, and not a dose any study has shown to be safe or effective.
| Parameter | Commonly reported |
|---|---|
| Amount | ~50–150 mg/day |
| Route | Oral (capsule) |
| Pattern | Once daily, time-limited |
Unlike most compounds on this site, 5-Amino-1MQ is taken orally, so there is no reconstitution or injection. That convenience can make it feel low-stakes, but the absence of human data cuts the other way: there is no clinical basis for the dose, no human safety record, and no confirmation that the appealing mouse-and-cell findings translate to people.
Status
5-Amino-1MQ is not FDA approved; it circulates as a research compound. Its mechanistic story connects to NAD+ biology (see the NAD+ dosage page), but mechanism is not evidence of human benefit. See the Regulatory Status Tracker for how such compounds are handled.
Frequently asked questions
If it raises NAD+, is it like taking NAD+?
The proposed mechanism is indirect — inhibiting an enzyme to spare NAD+ — but neither approach has strong human outcome data, and they are different molecules with different (and largely unproven) profiles.
Is oral dosing safer than injecting?
Oral avoids injection risks, but the deeper issue is the complete lack of human trial data on dose, safety, and effect — which oral convenience does not resolve.
Why is it on a peptide site?
It is constantly bundled with peptides in fat-loss and longevity discussion; we include it while being explicit that it is a small molecule, not a peptide.
Sources
- Kraus D, et al. "Nicotinamide N-methyltransferase knockdown protects against diet-induced obesity." Nature. 2014;508:258–262.
- Neelakantan H, et al. Small-molecule NNMT inhibitors (preclinical metabolic studies).
Medical disclaimer: Education only, not medical advice. 5-Amino-1MQ is investigational with no human trials and is not approved. Dosing figures reflect community reports, not a recommendation. Consult a licensed clinician.